相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis
Andreas E. Kremer et al.
LIVER INTERNATIONAL (2022)
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase
Carla F. Murillo Perez et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Beyond Biochemical Responses, Use of Histologic Staging to Predict Outcomes of Patients With Primary Biliary Cholangitis
Aliya F. Gulamhusein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
New treatments/targets for primary biliary cholangitis
Christophe Corpechot et al.
JHEP REPORTS (2019)
Management of Chronic Hepatic Itch
Miriam M. Duell et al.
DERMATOLOGIC CLINICS (2018)
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C. Corpechot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Ascending Pathophysiology of Cholestatic Liver Disease
Peter L. M. Jansen et al.
HEPATOLOGY (2017)
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
Gideon M. Hirschfield et al.
JOURNAL OF HEPATOLOGY (2017)
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
David Jones et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
The Selective Peroxisome Proliferator-Activated Receptor-Delta Agonist Seladelpar Reverses Nonalcoholic Steatohepatitis Pathology by Abrogating Lipotoxicity in Diabetic Obese Mice
Fahrettin Haczeyni et al.
HEPATOLOGY COMMUNICATIONS (2017)
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield et al.
GASTROENTEROLOGY (2015)
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy
Willem J. Lammers et al.
GASTROENTEROLOGY (2015)
The immunogenetics of primary biliary cirrhosis: A comprehensive review
G. J. Webb et al.
JOURNAL OF AUTOIMMUNITY (2015)
Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study
Willem J. Lammers et al.
GASTROENTEROLOGY (2014)
Liver X Receptor β and Peroxisome Proliferator-Activated Receptor δ Regulate Cholesterol Transport in Murine Cholangiocytes
Xuefeng Xia et al.
HEPATOLOGY (2012)
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Keiko Iwaisako et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome
Christophe Corpechot et al.
JOURNAL OF HEPATOLOGY (2011)
Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis
Teru Kumagi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid
Edith M. M. Kuiper et al.
GASTROENTEROLOGY (2009)
Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux
Carlos L. J. Vrins et al.
JOURNAL OF LIPID RESEARCH (2009)
Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance
Justin I. Odegaard et al.
CELL METABOLISM (2008)
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Christophe Corpechot et al.
HEPATOLOGY (2008)
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid
A Parés et al.
GASTROENTEROLOGY (2006)
分享论文
